Citius Oncology, Inc. Reports 2026 Annual Meeting Results; Directors Re-elected

What Happened

• On September 29, 2026, Citius Oncology, Inc. held its 2026 annual meeting of stockholders and announced the election of Class II directors Dr. Eugene Holuka, Robert Smith, and Carol Webb to three-year terms expiring at the 2029 annual meeting. Vote totals were: Dr. Eugene Holuka — 67,835,202 for, 8,267,153 withheld, 6,255,142 broker non-votes; Robert Smith — 67,883,403 for, 8,218,952 withheld, 6,255,142 broker non-votes; Carol Webb — 67,895,374 for, 8,206,981 withheld, 6,255,142 broker non-votes.
• Stockholders also ratified Wolf & Company, P.C. as Citius Oncology’s independent registered public accounting firm for the fiscal year ended September 30, 2026 (73,533,649 for; 8,809,478 against; 14,370 abstaining; no broker non-votes).

Key Details

• Meeting date: September 29, 2026.
• Directors elected: Dr. Eugene Holuka, Robert Smith, Carol Webb — three-year terms through the 2029 annual meeting.
• Auditor ratified: Wolf & Company, P.C. for FY ended Sept. 30, 2026 — 73,533,649 votes in favor.
• Broker non-votes recorded for director elections: 6,255,142 shares.

Why It Matters

• The results confirm board continuity with three Class II directors re-elected and no change to the company’s independent auditor for the stated fiscal year. For investors, this signals stability in governance and continuity in the company’s external audit relationship. The recorded withheld and against votes show a measurable minority dissent on director and auditor matters, but all proposals were approved and are now effective.